Ipilimumab vs Rosuvastatin
Ipilimumab vs Rosuvastatin: Overview
This comparison examines the pharmacological differences between Ipilimumab and Rosuvastatin.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Rosuvastatin: Competitive inhibitor of HMG-CoA reductase.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Rosuvastatin β 19 hours.
Chemical Properties
Molecular Formula: Rosuvastatin β C22H28FN3O6S.
Molecular Weight: Rosuvastatin β 481.5390 g/mol.
Type: Ipilimumab β Antibody; Rosuvastatin β Small molecule.